Cite
Arechederra M, Bazai SK, Abdouni A, et al. ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. J Hepatol. 2020;74(4):893-906doi: 10.1016/j.jhep.2020.11.008.
Arechederra, M., Bazai, S. K., Abdouni, A., Sequera, C., Mead, T. J., Richelme, S., Daian, F., Audebert, S., Dono, R., Lozano, A., Gregoire, D., Hibner, U., Allende, D. S., Apte, S. S., & Maina, F. (2021). ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. Journal of hepatology, 74(4), 893-906. https://doi.org/10.1016/j.jhep.2020.11.008
Arechederra, Maria, et al. "ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma." Journal of hepatology vol. 74,4 (2021): 893-906. doi: https://doi.org/10.1016/j.jhep.2020.11.008
Arechederra M, Bazai SK, Abdouni A, Sequera C, Mead TJ, Richelme S, Daian F, Audebert S, Dono R, Lozano A, Gregoire D, Hibner U, Allende DS, Apte SS, Maina F. ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. J Hepatol. 2021 Apr;74(4):893-906. doi: 10.1016/j.jhep.2020.11.008. Epub 2020 Nov 13. PMID: 33197513.
Copy
Download .nbib